CRDF vs. COGT, SNDX, CMRX, CDMO, ORIC, QURE, AVXL, IMNM, GYRE, and PHAT
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Chimerix (CMRX), Avid Bioservices (CDMO), Oric Pharmaceuticals (ORIC), uniQure (QURE), Anavex Life Sciences (AVXL), Immunome (IMNM), Gyre Therapeutics (GYRE), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs. Its Competitors
Cogent Biosciences (NASDAQ:COGT) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.
In the previous week, Cogent Biosciences had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Cogent Biosciences and 4 mentions for Cardiff Oncology. Cogent Biosciences' average media sentiment score of 1.01 beat Cardiff Oncology's score of 0.94 indicating that Cogent Biosciences is being referred to more favorably in the media.
Cogent Biosciences has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Cardiff Oncology has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Cogent Biosciences currently has a consensus target price of $14.43, suggesting a potential upside of 94.72%. Cardiff Oncology has a consensus target price of $9.88, suggesting a potential upside of 175.07%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Cogent Biosciences.
Cogent Biosciences has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. Cardiff Oncology's return on equity of -76.45% beat Cogent Biosciences' return on equity.
16.3% of Cardiff Oncology shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Cardiff Oncology beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 7/2/2025 by MarketBeat.com Staff
